We are pleased to announce that following the completion of the Marketing Authorization Holder (MAH) transfer for ‌Hasten’s Stilamin^® (Somatostatin) in the Greater China and Switzerland, the product has upgraded its packaging after passing regulatory compliance procedures and been officially implemented across all authorized territories.

To keep up with healthcare professionals, patients and partners during the transition, ‌Hasten hereby clarifies the following:

‌- Packaging updates‌ include the replacement of the original Merck branding with ‌Hasten branding, Hasten, or its authorized local partner identifiers‌, updated MAH information and local contact details according to the related regulation, which covering the adjustments of the box, labels, and package inserts, etc..

- ‌No changes‌ have been made to manufacturing site, raw materials, formulation, manufacturing processes or quality control standards, ensuring ‌uncompromised safety and efficacy;

- During the rollout phasing, ‌both old and new packaging‌ may coexist in the market temporarily.

The refreshed packaging for Stilamin^® not only reflects an updated corporate identity but also demonstrates ‌Hasten’s strict compliance with regulatory requirements as a responsible pharmaceutical company.

According to our global expansion strategy, ‌Hasten‌ has established a footprint spanning from South Korea in the East to Switzerland in the West and Australia in the South. Moving forward, we will accelerate MAH transfers for our product pipelines across Pan-Asia regions, including Thailand, Singapore, Hong Kong S.A.R., China and other regions gradually.

Rooted in China, Think Globally. This milestone further highlights the enhanced capabilities of Hasten’s ‌MAH framework, marking another breakthrough in our end-to-end lifecycle management of pharmaceutical products.